~~<i id='12EF291A2D'><strike id='12EF291A2D'><tt id='12EF291A2D'><pre id='12EF291A2D'></pre></tt></strike></i>~~

00:00

00:00 00:00 LIVE

buffering

Replay

hotspot

explore

author：leisure time 2025-10-02 15:14:38 - browse：27

Adam's take main illustration — Molly Ferguson/STAT

Biotech is awash in PIPEs.

The numbers behind these privately negotiated purchases of public-company stock are astounding. By my count, there have been 30 PIPE transactions involving public biotechs and institutional investors (mostly hedge funds) that have raised $4 billion in the first two months of the year.

Just this week, five biotechs have brought in a combined $950 million via PIPEs, including Denali Therapeutics raising $500 million, the largest such financing this year. Crinetics Pharmaceuticals raised $350 million.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Psychedelics group wrestles with new pharma identity
Next article： Healthy food access boosts outcomes in two studies

focus

Wikipedia

knowledge

entertainment

focus

JustinSullivan/GettyImagesTheassaultonthedevelopmentofnewlifesavingtherapiescontinuesapace.Recently,

WSS

How state and local governments are sidelining science

Medical school prerequisites are outdated

Medical mystery: When a cough is not just a cough

The dental labor crisis is a moment of opportunity

Private equity deals in Medicare Advantage declines

NIH chief: government has fallen behind pharma on clinical trials

hotspot

explore

focus

Drug repurposing or repositioning? The language matters

Study suggests Covid rebound is far more common with Paxlovid than without

Guidelines to prevent youth baseball injuries need more muscle

FDA cancer chief on how to get things done: ‘Don’t tell anybody'

Biden outlines 'new path' to provide student loan relief after Supreme Court rejection

Eli Lilly’s chief scientist on obesity drugs, gene editing, and more

Novavax promises a turnaround & Lilly roils the obesity market

A letter from the executive editor: STAT UnitedHealth investigation

Sports medicine is finally prioritizing gender equality

Private equity deals in Medicare Advantage declines

Wikipedia

NIH chief: government has fallen behind pharma on clinical trials

A ‘polypill’ could sharply reduce cardiovascular disease in the U.S.

NIH chief: government has fallen behind pharma on clinical trials

Today's health inequities arise from racist U.S. history, say experts

Carbon Health diabetes program, a test of data

Industry veterans launch new biotech VC with $310M

knowledge

knowledge

entertainment

focus